How psilocybin eased my cancer suffering
Herald Sun, March 9, 2021
Follows the story of Candian, Thomas Hartle, who has utilized psilocybin therapies to ease the suffering and pain from his stage 4 colon cancer.
NYU is Launching a Center for Psychedelic Medicine
Freethink, March 7, 2021
NYU’s Langone Health joins the research renaissance.
Greens MP hopes Canberra will be the first to introduce psychedelic assisted therapy
The Canberra Times, March 7, 2021
ACT Greens’ MLA Johnathan Davis wants Canberra to be the first jurisdiction to provide an accessible path for psychiatrists to prescribe psychedelic-assisted therapy to patients experiencing serious mental concerns.
Study Reveals More People are Using Psychedelics to Self-Treat Mental Health
Vice, March 5, 2021
The use of psychedelic medicines as an underground self-treatment for mental health conditions is on the rise, according to the world’s largest drug survey, with thousands of people turning to substances like LSD, MDMA, psilocybin and ketamine to treat psychiatric illnesses and emotional distress.
Why the TGA should down-schedule psilocybin and MDMA
Honi Soit, February 26, 2021
The Therapeutic Goods Administration should lead the way in destigmatising psychedelics.
Demand for illegal drugs in therapy
The Australian, February 21, 2021
After an interim decision by the health regulator rejected an application to make psilocybin and MDMA more accessible for psychiatrists to treat mental illness, patients are increasingly turning to illicit treatments.
Proposed California Law Would Legalize Magic Mushrooms, MDMA, LSD, And Other Psychedelic Drugs
Forbes, February 18, 2021
A proposal that would allow the possession, cultivation, use, and “sharing” of most psychedelic medicines in California was formally introduced in the state Legislature on Thursday.
MDMA proves a promising alcoholism treatment in world-first trial
TIME, February 17, 2021
Can psychedelic drugs treat depression? That’s the promise of findings from Robin Carhart-Harris, whose research is advancing a once fringe idea.
Young people’s despair over coronavirus deepens as crisis drags on
SMH, February 15, 2021
With curfews, closures and lockdowns in European countries set to drag into the northern spring or even the summer, mental health professionals are growing increasingly alarmed about the deteriorating mental state of young people, who they say have been among the most badly affected by a world with a foreshortened sense of the future.
Trips out: regulator says no to ‘shrooms as treatment for mental illness
MSN, February 10, 2021
In an interim decision published last week, the regulator refused to reschedule psilocybin and MDMA as controlled medical substances, a classification which would allow doctors to more easily prescribe them for treatment.
Psychedelic drug memo sparks uproar
The Australian, February 9, 2021
The peak body for psychiatrists has been savaged by its own members for a “pitiful” clinical memorandum, which lay behind the health regulator’s preliminary decision not to reclassify psychedelic medicines.
Stroke victims to be given psychedelic drug DMT in groundbreaking study
Metro, February 4, 2021
Psychedelic medicine DMT could help stroke victims recover by rewiring their brains faster, according to the first clinical trial of its kind.
Psychedelics as Antidepressants
Scientific American, January 30, 2021
The treatments of the future may arise from a long-stigmatized class of medicines.
How ecstasy and psilocybin are shaking up psychiatry
Nature, January 27, 2021
Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.
Ketamine to treat depression and addiction at UK’s first medical psychedelic psychotherapy clinic
iNews, January 25, 2021
The medicine is to be used by Awakn Life Sciences when its centre opens in Bristol in March, explains its chief medical officer Dr Ben Sessa.
Unique magic mushroom microdosing study to begin in Australia
New Atlas, January 20, 2021
A novel Australian trial is set to investigate the popular yet still deeply unproven practice of microdosing psychedelics. The research promises to be the first exploration of naturalistic psilocybin microdosing in a lab-setting using a cutting-edge neuroimaging technique and a unique kind of trial protocol.
EXCLUSIVE: Florida Lawmaker Introducing Psilocybin Mushroom Legalization
Forbes, January 15, 2021
A Florida state lawmaker plans to introduce as soon as next week a bill that would legalize psilocybin-assisted therapy in the state.
Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO
CNBC, January 15, 2021
Headquartered in Berlin, ATAI is aiming to make psychedelic medicines that can be used to treat mental health disorders. Recognify, meanwhile, is specifically aiming to make a medicine that can be used to treat the cognitive impairment associated with schizophrenia, or CIAS.
COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care
Global News Wire, January 8, 2021
COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, is establishing its first Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, United States.
Mount Sinai Health System Launches Center for Psychedelic Research
Psychedelic Finance, January 8, 2021
The Icahn School of Medicine at Mount Sinai has launched a new center for psychedelics research. The Center for Psychedelic Psychotherapy and Trauma Research pursues a multi-pronged clinical and research approach to discovering novel and more efficacious therapies for post-traumatic stress disorder (PTSD), depression, anxiety, and other stress-related conditions in the veteran and civilian population.